| Added by | pcoopman |
|---|---|
| Group name | EquipePC |
| Item Type | Journal Article |
| Title | Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 |
| Creator | Berger et al. |
| Author | Margaux Marce |
| Author | Suzette Delaloge |
| Author | Anne-Claire Hardy-Bessard |
| Author | Thomas Bachelot |
| Author | Ivan Bièche |
| Author | Anne Pradines |
| Author | Thibault De La Motte Rouge |
| Author | Jean-Luc Canon |
| Author | Fabrice André |
| Author | Laurent Arnould |
| Author | Florian Clatot |
| Author | Jérôme Lemonnier |
| Author | Sandrine Marques |
| Abstract | INTRODUCTION: The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. However, most patients receiving this combination will ultimately progress and require further therapies.Several studies have demonstrated that the onset of a ESR1 gene mutation lead to AIs resistance in the advanced setting. ESR1 mutations can be detected in circulating tumour DNA (ctDNA) using a digital PCR assay. Our study aims to prove the clinical efficacy of periodic monitoring for emerging or rise of ESR1 mutations in ctDNA to trigger an early change from AI plus palbociclib to fulvestrant plus palbociclib treatment while assessing global safety. METHODS: PADA-1 is a randomised, open-label, multicentric, phase III trial conducted in patients receiving AI and palbociclib as first line therapy for metastatic ER +HER2- breast cancer. 1000 patients will be included and treated with palbociclib in combination with an AI. Patients will be screened for circulating blood ESR1 mutation detection at regular intervals. Patients for whom a rising circulating ESR1 mutation is detected without tumour progression (up to N=200) will be randomised (1:1) between (1) Arm A: no modification of therapy; and (2) Arm B: palbociclib in combination with fulvestrant, a selective ER down-regulator. At tumour progression, an optional crossover will be offered to patients randomised in arm A. The coprimary endpoints are (1) Grade ?3 haematological toxicities and their associations with baseline characteristics and (2) progression-free survival in randomised patients. ETHICS AND DISSEMINATION: The study has been approved by the French medicines agency (ANSM) and by an ethics committee (ref 01/17_1 CPP Ouest-IV Nantes) in January 2017. The trial results will be published in academic conference presentations and international peer-reviewed journals. TRIAL REGISTRATION NUMBERS: EudraCT: 2016-004360-18; NCT03079011. |
| Publication | BMJ open |
| Volume | 12 |
| Issue | 3 |
| Pages | e055821 |
| Date | 2022-03-03 |
| Journal Abbr | BMJ Open |
| Language | eng |
| DOI | 10.1136/bmjopen-2021-055821 |
| ISSN | 2044-6055 |
| Short Title | Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patien |
| Library Catalog | PubMed |
| Extra | PMID: 35241469 PMCID: PMC8896060 |
| Tags | Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, breast tumours, clinic, Female, Fulvestrant, Humans, Mutation, Piperazines, Pyridines, Receptor, ErbB-2, Receptors, Estrogen |
| Date Added | 2023/11/20 - 18:12:46 |
| Date Modified | 2023/11/20 - 18:12:59 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
